ONO-2020 – Epigenetic regulator
Alzheimer’s disease
About This Program
ONO-2020, an investigational compound, is being investigated in a Phase 2 trial in the U.S. to evaluate safety, tolerability, pharmacokinetics and efficacy of ONO-2020 in participants with mild to moderate Alzheimer's disease.
To learn more about this study, click here.